Parkinsons Disease Therapeutics Market

By Disease Type;

Familial Parkinsons Disease, Idiopathic Parkinsons Disease, and Induced Parkinsonism

By Treatment Type;

Carbidopa or Levodopa Enteral Suspension, Medication, and Surgical Therapy

By Administration Route;

Intestinal Infusion, Oral, Subcutaneous, Transdermal, and Others

By Distribution Channel;

Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn125697754 Published Date: June, 2025 Updated Date: July, 2025

Parkinsons Disease Therapeutics Market Overview

Parkinsons Disease Therapeutics Market (USD Million)

Parkinsons Disease Therapeutics Market was valued at USD 6,765.28 million in the year 2024. The size of this market is expected to increase to USD 10,787.97 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.9%.


Parkinsons Disease Therapeutics Market

*Market size in USD million

CAGR 6.9 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.9 %
Market Size (2024)USD 6,765.28 Million
Market Size (2031)USD 10,787.97 Million
Market ConcentrationMedium
Report Pages329
6,765.28
2024
10,787.97
2031

Major Players

  • AbbVie Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim GmbH
  • UCB S.A.
  • Astellas Pharma Inc.
  • Sunovion Pharmaceuticals Inc.
  • Lundbeck A/S

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Parkinsons Disease Therapeutics Market

Fragmented - Highly competitive market without dominant players


The Parkinson’s Disease Therapeutics Market is undergoing rapid transformation driven by the adoption of advanced treatment modalities. An increasing share of over 35% of development activity is focused on innovative therapies, including targeted pharmaceuticals and neuromodulation systems. This push for innovation is creating new opportunities and helping companies align with the evolving expectations of personalized care.

Drug Discovery Fueled by Strategic Collaborations
A robust pipeline of dopamine-centric treatments and precision therapeutics now captures around 40% of the neuropharmaceutical research landscape. Companies are enhancing their R&D efficiency through strategic partnerships, fueling growth in therapeutic effectiveness and market responsiveness. These collaborations play a pivotal role in optimizing drug development strategies and improving success rates.

Technology Empowering Therapeutic Efficiency
Innovations in wearable monitoring devices and smart drug delivery systems are being adopted in over 30% of therapeutic settings. These advancements enable more accurate treatment regimens and promote better patient compliance. The rising application of technological advancements is opening up new strategies for expanding treatment access and improving disease management.

Strong Investment Supporting Future Development
An optimistic future outlook is backed by growing investments and public-private funding, with more than 28% directed toward neurodegenerative therapies. This surge in capital is driving the expansion of advanced treatment platforms and supporting innovation across multiple therapeutic approaches. These financial inflows are expected to further accelerate development across the Parkinson’s care spectrum.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Disease Type
    2. Market Snapshot, By Treatment Type
    3. Market Snapshot, By Administration Route
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Parkinson’s Disease Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing prevalence of Parkinson's disease
        2. Advancements in drug development and research
        3. Growing awareness and early diagnosis
      2. Restraints
        1. High cost of treatment
        2. Side effects associated with current therapies
        3. Limited access to healthcare in developing regions
      3. Opportunities
        1. Development of novel therapeutics and personalized medicine
        2. Increasing investment in research and development
        3. Expansion in emerging markets
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Parkinson’s Disease Therapeutics Market, By Disease Type, 2021 - 2031 (USD Million)
      1. Familial Parkinson's Disease
      2. Idiopathic Parkinson's Disease
      3. Induced parkinsonism
    2. Parkinson’s Disease Therapeutics Market, By Treatment Type, 2021 - 2031 (USD Million)
      1. Medication
      2. Surgical Therapy
      3. Carbidopa/Levodopa Enteral Suspension.
    3. Parkinson’s Disease Therapeutics Market, By Administration Route, 2021 - 2031 (USD Million)
      1. Transdermal
      2. Oral
      3. Subcutaneous
      4. Intestinal Infusion
      5. Others
    4. Parkinson’s Disease Therapeutics Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    5. Parkinson’s Disease Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Roche
      2. Pfizer
      3. Novartis AG
      4. Merck & Co., Inc.
      5. GlaxoSmithKline plc (GSK)
      6. Teva Pharmaceutical Industries Ltd.
      7. AbbVie, Inc.
      8. UCB
      9. H. Lundbeck A/S
      10. Boehringer Ingelheim International GmbH
      11. Amneal Pharmaceuticals LLC

Neurocrine Biosciences

  1. Analyst Views
  2. Future Outlook of the Market